AR068349A1 - PROSTAGLANDIN AGONIST POLYMORPHES AND PROCEDURES TO MANUFACTURE THE SAME - Google Patents
PROSTAGLANDIN AGONIST POLYMORPHES AND PROCEDURES TO MANUFACTURE THE SAMEInfo
- Publication number
- AR068349A1 AR068349A1 ARP080103712A ARP080103712A AR068349A1 AR 068349 A1 AR068349 A1 AR 068349A1 AR P080103712 A ARP080103712 A AR P080103712A AR P080103712 A ARP080103712 A AR P080103712A AR 068349 A1 AR068349 A1 AR 068349A1
- Authority
- AR
- Argentina
- Prior art keywords
- crystalline form
- diffraction pattern
- powder
- ray diffraction
- values measured
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000002522 prostaglandin receptor stimulating agent Substances 0.000 title 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 7
- 230000005855 radiation Effects 0.000 abstract 7
- WOHRHWDYFNWPNG-UHFFFAOYSA-N evatanepag Chemical compound C1=CC(C(C)(C)C)=CC=C1CN(S(=O)(=O)C=1C=NC=CC=1)CC1=CC=CC(OCC(O)=O)=C1 WOHRHWDYFNWPNG-UHFFFAOYSA-N 0.000 abstract 5
- 159000000000 sodium salts Chemical class 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 2
- 238000002441 X-ray diffraction Methods 0.000 abstract 1
- -1 compound sodium salt Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Rheumatology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente se refiere a formas cristalinas polimorficas o a una forma no cristalina o amorfa del compuesto sal sodica del ácido (3-(((4-terc-butil-bencil)-(piridin-3-sulfonil)-amino)-metil)-fenoxi)-acético o un hidrato del mismo conjuntamente con procedimientos para preparar, procedimientos para usar, y composiciones farmacéuticas que contengan las mismas. La invencion se refiere también a formas cristalinas polimorficas sustancialmente puras o una forma no cristalina o forma amorfa de la sal sádica del ácido (3-(((4-terc-butil-bencil)-(piridin-3-sulfonil)-amino)-metil)-fenoxi)-acético o de un hidrato de la misma. Reivindicacion 1: Una forma cristalina de la sal sodica del ácido (3-(((4-terc-butil-bencil)- (piridin-3-sulfonil)-amino)-metil)-fenoxi)-acético o un hidrato de la misma. Reivindicacion 3: La forma cristalina de acuerdo con la reivindicacion 1, en la que: la forma cristalina es forma cristalina A; y el patron de difraccion de rayos X en polvo contiene los siguientes valores de 2 theta medidos usando radiacion de CuKalfa: 3,2, 4,1, 16,1, 20,2 y 20,8. Reivindicacion 6: La forma cristalina de acuerdo con la reivindicacion 1, en la que: la forma cristalina es forma cristalina B; y el patron de difraccion de rayos X en polvo contiene los siguientes valores de 2 theta medidos usando radiacion de CuKalfa: 3,2, 3,6, 7,1, 8,4 y 13,8. Reivindicacion 9: La forma cristalina de acuerdo con la reivindicacion 1, en la que: la forma cristalina es forma cristalina C; y el patron de difraccion de rayos X en polvo contiene los siguientes valores de 2 theta medidos usando radiacion de CuKalfa: 3,2, 4,0, 5,9, 13,3 y 16,9. Reivindicacion 12: La forma cristalina de acuerdo con la reivindicacion 1, en la que: la forma cristalina es forma cristalina E; y el patron de difraccion de rayos X en polvo contiene los siguientes valores de 2 theta medidos usando radiacion de CuKalfa: 7,0, 14,1, 21,2, 20,2 y 28,5. Reivindicacion 14: La forma cristalina de acuerdo con la reivindicacion 1, en la que: la forma cristalina es forma cristalina F; y el patron de difraccion de rayos X en polvo contiene los siguientes valores de 2 theta medidos usando radiacion de CuKalfa: 5,5, 8,2, 11,0, 19,2 y 27,5. Reivindicacion 16: La forma cristalina de acuerdo con a reivindicacion 1, en la que: la forma cristalina es forma cristalina G; y el patron de difraccion de rayos X en polvo contiene los siguientes valores de 2 theta medidos usando radiacion de CuKalfa: 3,2, 4,0, 7,9, 10,0 y 13,1. Reivindicacion 26: Una forma no cristalina de la sal sodica del ácido (3-(((4-terc-butil-bencil)-(piridin-3-sulfonil)-amino)-metil)-fenoxi)-acético o un hidrato de la misma, en la que la forma no cristalina es forma no cristalina H; y el patron de difraccion en polvo de rayos X contiene los siguientes valores de 2 theta medidos usando radiacion de CuKalfa,: 3,1. Reivindicacion 28: Una forma amorfa de la sal sodica del ácido (3-(((4-terc-butil-bencil)-(piridin-3-sulfonil)-amino)-metil)-fenoxi)-acético o un hidrato de la misma, en la que la forma amorfa es forma amorfa I; y el patron de difraccion de rayos X es sustancialmente como se muestra en la figura 6C.This refers to polymorphic crystalline forms or a non-crystalline or amorphous form of the compound sodium salt of the acid (3 - (((4-tert-butyl-benzyl) - (pyridin-3-sulfonyl) -amino) -methyl) - phenoxy) -acetic acid or a hydrate thereof in conjunction with methods for preparing, procedures for use, and pharmaceutical compositions containing the same. The invention also relates to substantially pure polymorphic crystalline forms or a non-crystalline form or amorphous form of the sadic acid salt (3 - (((4-tert-butyl-benzyl) - (pyridin-3-sulfonyl) -amino) -methyl) -phenoxy) -acetic acid or a hydrate thereof. Claim 1: A crystalline form of the sodium salt of the (3 - (((4-tert-butyl-benzyl) - (pyridin-3-sulfonyl) -amino) -methyl) -phenoxy) -acetic acid or a hydrate of the same. Claim 3: The crystalline form according to claim 1, wherein: the crystalline form is crystalline form A; and the powder X-ray diffraction pattern contains the following 2 theta values measured using CuKalfa radiation: 3.2, 4.1, 16.1, 20.2 and 20.8. Claim 6: The crystalline form according to claim 1, wherein: the crystalline form is crystalline form B; and the powder X-ray diffraction pattern contains the following 2 theta values measured using CuKalfa radiation: 3.2, 3.6, 7.1, 8.4 and 13.8. Claim 9: The crystalline form according to claim 1, wherein: the crystalline form is crystalline form C; and the powder X-ray diffraction pattern contains the following 2 theta values measured using CuKalfa radiation: 3.2, 4.0, 5.9, 13.3 and 16.9. Claim 12: The crystalline form according to claim 1, wherein: the crystalline form is crystalline form E; and the powder X-ray diffraction pattern contains the following 2 theta values measured using CuKalfa radiation: 7.0, 14.1, 21.2, 20.2 and 28.5. Claim 14: The crystalline form according to claim 1, wherein: the crystalline form is crystalline form F; and the powder X-ray diffraction pattern contains the following 2 theta values measured using CuKalfa radiation: 5.5, 8.2, 11.0, 19.2 and 27.5. Claim 16: The crystalline form according to claim 1, wherein: the crystalline form is crystalline form G; and the powder X-ray diffraction pattern contains the following 2 theta values measured using CuKalfa radiation: 3.2, 4.0, 7.9, 10.0 and 13.1. Claim 26: A non-crystalline form of the sodium salt of the (3 - (((4-tert-butyl-benzyl) - (pyridin-3-sulfonyl) -amino) -methyl) -phenoxy) -acetic acid or a hydrate of the same, in which the non-crystalline form is non-crystalline form H; and the X-ray powder diffraction pattern contains the following 2 theta values measured using CuKalfa radiation: 3.1. Claim 28: An amorphous form of the sodium salt of the (3 - (((4-tert-butyl-benzyl) - (pyridin-3-sulfonyl) -amino) -methyl) -phenoxy) -acetic acid or a hydrate of the same, in which the amorphous form is amorphous form I; and the X-ray diffraction pattern is substantially as shown in Figure 6C.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96877107P | 2007-08-29 | 2007-08-29 | |
| US8355908P | 2008-07-25 | 2008-07-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR068349A1 true AR068349A1 (en) | 2009-11-11 |
Family
ID=40042625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103712A AR068349A1 (en) | 2007-08-29 | 2008-08-27 | PROSTAGLANDIN AGONIST POLYMORPHES AND PROCEDURES TO MANUFACTURE THE SAME |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP2185516A2 (en) |
| JP (1) | JP2009137934A (en) |
| KR (1) | KR20100050559A (en) |
| CN (1) | CN101842356A (en) |
| AR (1) | AR068349A1 (en) |
| AU (1) | AU2008291814A1 (en) |
| CA (1) | CA2697950A1 (en) |
| MX (1) | MX2010002300A (en) |
| WO (1) | WO2009027811A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102356080B (en) | 2009-02-27 | 2015-04-29 | 奥索-麦克尼尔-詹森药品公司 | Amorphous salts of HCV macrocyclic inhibitors |
| KR102058853B1 (en) * | 2018-02-28 | 2019-12-24 | 브릿지바이오테라퓨틱스(주) | Water soluble salts of lipidated peptides and methods for preparing and using the same |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA67754C2 (en) * | 1997-10-10 | 2004-07-15 | Пфайзер, Інк. | Prostaglandin agonists and use thereof for the treatment of bone disorders |
-
2008
- 2008-08-25 CA CA2697950A patent/CA2697950A1/en not_active Abandoned
- 2008-08-25 MX MX2010002300A patent/MX2010002300A/en not_active Application Discontinuation
- 2008-08-25 WO PCT/IB2008/002252 patent/WO2009027811A2/en not_active Ceased
- 2008-08-25 KR KR1020107006782A patent/KR20100050559A/en not_active Ceased
- 2008-08-25 CN CN200880113737A patent/CN101842356A/en active Pending
- 2008-08-25 EP EP08806952A patent/EP2185516A2/en not_active Withdrawn
- 2008-08-25 AU AU2008291814A patent/AU2008291814A1/en not_active Abandoned
- 2008-08-27 AR ARP080103712A patent/AR068349A1/en not_active Application Discontinuation
- 2008-08-28 JP JP2008218939A patent/JP2009137934A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA2697950A1 (en) | 2009-03-05 |
| EP2185516A2 (en) | 2010-05-19 |
| JP2009137934A (en) | 2009-06-25 |
| KR20100050559A (en) | 2010-05-13 |
| AU2008291814A1 (en) | 2009-03-05 |
| MX2010002300A (en) | 2010-03-18 |
| WO2009027811A2 (en) | 2009-03-05 |
| CN101842356A (en) | 2010-09-22 |
| WO2009027811A3 (en) | 2009-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR114946A2 (en) | CRYSTALLINE FORMS OF 3- (2,6-DICHLORO-3,5-DIMETOXY-PHENYL) -1- {6- [4- (4-ETHYL-PIPERAZIN-1-IL) -PHENYL-AMINO] -PYRIMIDIN-4- IL} -1-METHYL-UREA AND SALTS OF THE SAME | |
| BR112015012425A2 (en) | compound, pharmaceutical composition, method and medicament for the treatment of diseases medicated by parp-1 protein and use of the compound | |
| ECSP18063798A (en) | AN AMORPHOUS FORM AND A GENZ 112638 HEMITARTRATE CRYSTALLINE AS A GLUCOSYLCERAMIDE SYNTHASE INHIBITOR | |
| AR084903A1 (en) | FUSED AMINODIHYDROTIAZINE DERIVATIVES | |
| UY32096A (en) | DERIVATIVES OF 2-CARBOXAMIDE - CICLOAMINO - UREA SPECIFIC, ITS PHARMACUTICALLY ACCEPTABLE SALTS, COMPOSITIONS CONTAINING THEM, PRO-PHARMACES OF THE SAME, PROCESSES FOR PRODUCTION AND APPLICATIONS | |
| UA129695C2 (en) | METHOD OF PREPARATION AND CRYSTALLINE FORMS OF INTERMEDIATE PRODUCT IN THE SYNTHESIS OF MDM2 INHIBITOR | |
| PE20120989A1 (en) | DISACARINE SALTS, DIFFUMARIC ACID, D-1-HYDROXY-2-NAPHTHOIC ACID AND MONOBENZOIC OF 2- (4 - ((2-AMINO-4-METHYL-6- (PENTILAMINO) PYRIMIDIN-5-IL) METHYL) PHENYL) 4- (DIMETHYLAMINE) BUTYL ACETATE | |
| ECSP13012770A (en) | CRYSTAL FORMS OF 5-CHLORINE-N2- (2-ISOPROPOXI-5-METHYL-4-PIPERIDIN-4-IL-PHENYL) -N4- [2- (PROPAN-2-SULPHONYL) -PENYL] -PIRIMIDIN-2,4 -DIAMINE | |
| ECSP099818A (en) | PROCESSES FOR THE PREPARATION OF PIRAZOLES | |
| AR066130A1 (en) | CRYSTAL FORMS OF SAXAGLIPTINA AND PROCESSES TO PREPARE THE SAME | |
| UY33317A (en) | NEW DERIVATIVES OF PIRAZOL | |
| CO6700837A2 (en) | Processing process for prrimidine derivatives | |
| AR088018A1 (en) | PROCESS AND INTERMEDIARIES TO PREPARE LAPATINIB | |
| BRPI0905147A8 (en) | process for synthesizing ivabradine and its addition salts with a pharmaceutically acceptable acid | |
| PE20211756A1 (en) | NOVEL POLYMORPHIC FORMS OF A TGFß INHIBITOR | |
| MX2022015151A (en) | PROCESSES TO PREPARE 3-(3-(3,5-DIMETHYL-1H-PYRAZOLE-4-IL)PRO POXI)-4- 5-FLUOROBENZOIC ACID (AG-10), ITS INTERMEDIATE COMPOUNDS, AND SALTS THEREOF. | |
| CU20130116A7 (en) | HETEROARILO DERIVATIVES AS MODULATORS OF NACHR ALFA 7 | |
| CU24330B1 (en) | ACID DERIVATIVES 4 - ((1,1) BIFENIL-4-IL) -3- (3-PHOSPHONOPROPANAMIDE) BUTANOIC, ASSETS AS NEP INHIBITORS (NEUTRAL ENDOPEPTIDASE) | |
| AR079932A1 (en) | METHOD FOR THE PREPARATION OF NEBIVOLOL AND INTERMEDIATE COMPOUNDS. | |
| CO6270323A2 (en) | SOLID FORMS OF ACID (S) -2-AMINO-3- (4- (2-AMINO-6 - ((R) -2,2,2-TRIFLUORO- 1- (3'-METOXIBIFENIL-4-IL) ETOXI ) PIRIMIDIN-4-IL) PHENYL) PROPANOIC AND METHODS FOR USE | |
| CL2011001405A1 (en) | Procedure for the preparation of n- [2- (7-methoxy-1-naphthyl) ethyl] acetamide, agomethalin. | |
| MX2019009224A (en) | DIACILHIDRAZINA CRISTALINA AND ITS USES. | |
| CL2011001829A1 (en) | 3'-n-desmethyl-4 '' - o- (2-diethylaminoetanoyl) -6-o-methyl-9a-aza-9a-homoerythromycin a, its salts and crystalline forms 1, 2 and 3; Preparation process; use to treat inflammatory diseases; pharmaceutical composition; and composition which also comprises another active compound. | |
| CO6321280A2 (en) | NEW ESPIRO PIPERIDINAS CLASS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | |
| ECSP13012548A (en) | OXADIAZOL INHIBITORS OF LEUCOTRENE PRODUCTION. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |